Chengdu Bright Eye Hospital Group Co., Ltd. (301239.SZ)
- Previous Close
41.21 - Open
40.88 - Bid 41.17 x --
- Ask 41.20 x --
- Day's Range
41.11 - 42.75 - 52 Week Range
28.48 - 63.72 - Volume
2,157,557 - Avg. Volume
2,850,691 - Market Cap (intraday)
6.176B - Beta (5Y Monthly) 0.90
- PE Ratio (TTM)
-- - EPS (TTM)
-0.22 - Earnings Date --
- Forward Dividend & Yield 0.40 (0.97%)
- Ex-Dividend Date Jul 22, 2024
- 1y Target Est
67.00
Chengdu Bright Eye Hospital Group Co., Ltd., a specialized chain medical institution company, engages in the provision of ophthalmic general medical services in China. Its ophthalmology institutions provide diagnosis, treatment, health care, and medical optometry for patients with ophthalmic diseases in the areas of refractive surgery, cataract, ophthalmology, fundus disease, glaucoma, strabismus and pediatric ophthalmology, lacrimal duct, cornea orbital disease, eye trauma, medical optometry, and other general ophthalmology diagnosis and treatment items. The company was formerly known as Chengdu Bright Eye Hospital Co., Ltd. and changed its name to Chengdu Bright Eye Hospital Group Co., Ltd. in July 2024. The company was founded in 2006 and is headquartered in Shanghai, China.
www.purui.cn4,918
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: 301239.SZ
View MorePerformance Overview: 301239.SZ
Trailing total returns as of 4/25/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 301239.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 301239.SZ
View MoreValuation Measures
Market Cap
6.17B
Enterprise Value
7.43B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.23
Price/Book (mrq)
2.78
Enterprise Value/Revenue
2.76
Enterprise Value/EBITDA
63.21
Financial Highlights
Profitability and Income Statement
Profit Margin
-1.25%
Return on Assets (ttm)
1.82%
Return on Equity (ttm)
-1.07%
Revenue (ttm)
2.69B
Net Income Avi to Common (ttm)
-33.49M
Diluted EPS (ttm)
-0.22
Balance Sheet and Cash Flow
Total Cash (mrq)
635.88M
Total Debt/Equity (mrq)
84.26%
Levered Free Cash Flow (ttm)
-246.24M